ID29061A - METODE DAN KOMPOSISI UNTUK MEMPERBAIKI STABILITAS KONFORMASI SUATU PROTEIN DARI KELUARGA p53 - Google Patents

METODE DAN KOMPOSISI UNTUK MEMPERBAIKI STABILITAS KONFORMASI SUATU PROTEIN DARI KELUARGA p53

Info

Publication number
ID29061A
ID29061A IDW00200101178A ID20011178A ID29061A ID 29061 A ID29061 A ID 29061A ID W00200101178 A IDW00200101178 A ID W00200101178A ID 20011178 A ID20011178 A ID 20011178A ID 29061 A ID29061 A ID 29061A
Authority
ID
Indonesia
Prior art keywords
family
protein
composition
improve
conformation stability
Prior art date
Application number
IDW00200101178A
Other languages
English (en)
Inventor
Heather Anne Coffey
Richard Damian Connell
Barbara Ann Foster
Farzan Rastinejad
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ID29061A publication Critical patent/ID29061A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IDW00200101178A 1998-12-02 1999-12-01 METODE DAN KOMPOSISI UNTUK MEMPERBAIKI STABILITAS KONFORMASI SUATU PROTEIN DARI KELUARGA p53 ID29061A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11054298P 1998-12-02 1998-12-02

Publications (1)

Publication Number Publication Date
ID29061A true ID29061A (id) 2001-07-26

Family

ID=22333594

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101178A ID29061A (id) 1998-12-02 1999-12-01 METODE DAN KOMPOSISI UNTUK MEMPERBAIKI STABILITAS KONFORMASI SUATU PROTEIN DARI KELUARGA p53

Country Status (25)

Country Link
US (1) US20020048271A1 (id)
EP (1) EP1137418A2 (id)
JP (2) JP2002531396A (id)
KR (1) KR20010086073A (id)
CN (1) CN1329493A (id)
AP (1) AP2001002153A0 (id)
AU (1) AU1290700A (id)
BG (1) BG105599A (id)
BR (1) BR9915940A (id)
CA (1) CA2350597A1 (id)
EA (1) EA003326B1 (id)
EE (1) EE200100302A (id)
HK (1) HK1041644A1 (id)
HR (1) HRP20010414A2 (id)
HU (1) HUP0201215A2 (id)
ID (1) ID29061A (id)
IL (1) IL143094A0 (id)
IS (1) IS5943A (id)
NO (1) NO20012737L (id)
OA (1) OA11722A (id)
PL (1) PL348310A1 (id)
TR (1) TR200101549T2 (id)
WO (1) WO2000032175A2 (id)
YU (1) YU35401A (id)
ZA (1) ZA200104210B (id)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US20030022243A1 (en) * 2001-06-20 2003-01-30 Les Kondejewski Protein aggregation assays and uses thereof
CA2454768A1 (en) * 2001-08-10 2003-02-20 Medical Research Council Molecule
US20050221324A1 (en) * 2002-05-06 2005-10-06 Fox Michael H Genotoxicity analysis
WO2004030671A2 (en) * 2002-10-02 2004-04-15 Merck Patent Gmbh Use of 4-amino-quinazolines as anti cancer agents
EP1470818B1 (en) * 2003-04-25 2006-07-26 Neuro3D Use of piperazine phenothiazine derivatives in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on cns and/or pns
US6970791B1 (en) * 2003-05-23 2005-11-29 Verachem, Llc Tailored user interfaces for molecular modeling
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
CN1984660B (zh) * 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
AU2004292546A1 (en) * 2003-11-21 2005-06-09 Merck & Co., Inc. Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain
EP1709973A1 (en) * 2003-12-24 2006-10-11 Locomogene, Inc. Method of suppressing cancer
JPWO2005061007A1 (ja) * 2003-12-24 2007-07-12 学校法人 聖マリアンナ医科大学 癌の抑制方法
CA2569404A1 (en) * 2004-06-04 2005-12-22 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
EP1915351A1 (en) * 2005-07-15 2008-04-30 Schering Corporation Quinazoline derivatives useful in cancer treatment
US7790474B1 (en) 2005-07-15 2010-09-07 Schering Corporation p53 modulators
CA2644643C (en) 2006-03-22 2015-05-19 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53
US8088795B2 (en) 2006-03-22 2012-01-03 Janssen Pharmaceutica N.V. Cyclic-alkylamine derivatives as inhibitors of the interaction between MDM2 and p53
NZ546477A (en) * 2006-04-07 2009-04-30 Auckland Uniservices Ltd 4-Alkylamino-2-(heterocyclic)quinazolines and their use in cancer therapy
US8318156B2 (en) 2006-07-10 2012-11-27 The Trustees Of Columbia University In The City Of New York Anti-cocaine compositions and treatment
WO2008155441A1 (en) * 2007-06-20 2008-12-24 Marikki Laiho Activators and therapeutic applications thereof
MX2010000410A (es) 2007-07-10 2010-05-24 Univ Columbia Termoestabilizacion de proteinas.
ES2534899T3 (es) 2007-08-06 2015-04-30 Janssen Pharmaceutica, N.V. Fenilendiaminas sustituidas como inhibidores de la interacción entre MDM2 y p53
SG173495A1 (en) 2009-02-04 2011-09-29 Janssen Pharmaceutica Nv Indole derivatives as anticancer agents
US20130102627A1 (en) * 2010-04-09 2013-04-25 The Brigham And Women's Hospital, Inc. Acridines As Inhibitors Of Haspin And DYRK Kinases
US9221760B2 (en) 2011-05-09 2015-12-29 Van Andel Research Institute Autophagy inhibitors
WO2013043744A2 (en) 2011-09-21 2013-03-28 Inception 1, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
CN102660257B (zh) * 2012-05-22 2013-11-27 南京邮电大学 吩噻嗪基喹唑啉类荧光离子探针及其应用
PT3201234T (pt) 2014-09-30 2019-02-05 Diadem S R L Anticorpo que se liga a um epitopo linear de p53 humana e suas aplicações em diagnóstico
CN105399670B (zh) * 2015-12-02 2018-04-17 广西中医药大学 一种苯并(c)吖啶酰胺基硫脲衍生物及其制备方法和用途
CN105418501B (zh) * 2015-12-02 2018-04-17 广西中医药大学 7‑对甲氧苯氨基苯并[c]吖啶盐酸盐及其制备方法和用途
CN105399671B (zh) * 2015-12-02 2018-04-17 广西中医药大学 7‑对甲苯氨基苯并[c]吖啶盐酸盐及其制备方法和用途
AU2017214733B2 (en) * 2016-02-04 2022-09-29 Yeda Research And Development Co. Ltd. Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53
CA3215564A1 (en) 2016-02-19 2017-08-24 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function
CN109694358B (zh) * 2019-01-23 2022-02-08 广西师范大学 2-对硝苯乙烯基-4-取代氨基喹唑啉衍生物及其制备方法和应用
EP4034104B1 (en) 2019-09-23 2025-08-06 PMV Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function
US12570645B2 (en) 2020-06-22 2026-03-10 Pmv Pharmaceuticals, Inc. Uses of p53 x-ray co-crystal structures
US20210405056A1 (en) * 2020-06-24 2021-12-30 Pmv Pharmaceuticals, Inc. Methods for detecting mutant p53 function
CN116096704A (zh) 2020-06-24 2023-05-09 皮姆维制药公司 用于治疗癌症的组合疗法
GB202111035D0 (en) * 2021-07-30 2021-09-15 Vestlandets Innovasjonsselskap As Therapy

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224784D0 (en) * 1992-11-26 1993-01-13 Univ Dundee Cellular protein
WO1995024483A1 (en) * 1994-03-08 1995-09-14 Scotgen Biopharmaceuticals, Inc. Recombinant humanized anti-fb5 antibodies
AU708829B2 (en) * 1994-12-13 1999-08-12 Human Genome Sciences, Inc. Human tissue inhibitor of metalloproteinase-4
US6107332A (en) * 1995-09-12 2000-08-22 The Liposome Company, Inc. Hydrolysis-promoting hydrophobic taxane derivatives
US6270954B1 (en) * 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
AU734905B2 (en) * 1996-04-10 2001-06-28 Regents Of The University Of California, The Correction of genetic defects using chemical chaperones
DE19624154A1 (de) * 1996-06-18 1998-01-08 Hoechst Ag Ringannelierte Dihydropyrane, Verfahren zur Herstellung sowie deren Verwendung
US5932613A (en) * 1996-07-03 1999-08-03 Millennium Pharmaceuticals, Inc. Anticancer agents
US5958892A (en) * 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
KR20000035920A (ko) * 1996-08-28 2000-06-26 데이비드 엠 모이어 헤테로고리성 메탈로프로테아제 저해제
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
US6387673B1 (en) * 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
US6284923B1 (en) * 1997-08-22 2001-09-04 Tularik Inc Substituted benzene compounds as antiproliferative and cholesterol lowering action
US6387903B1 (en) * 1997-08-27 2002-05-14 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6380395B1 (en) * 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
FI105554B (fi) * 1998-05-13 2000-09-15 Galilaeus Oy Geenimuunnelluista Streptomyces galilaeus-kannoista saatavat hybridiantrasykliinit
US6395749B1 (en) * 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
US5981564A (en) * 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
EP1104761B1 (en) * 1998-08-12 2004-10-13 Daiichi Pure Chemicals Co., Ltd. Fluorescent labelling reagents
SE9900941D0 (sv) * 1998-12-23 1999-03-16 Nomet Management Serv Bv Novel retinoic acid derivatives and their use
US6207700B1 (en) * 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
WO2000066125A1 (en) * 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6406699B1 (en) * 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
AU7847800A (en) * 1999-10-15 2001-04-30 Mayo Foundation For Medical Education And Research Topical anesthetics useful for treating cancer, autoimmune diseases and ischemia
US6372785B1 (en) * 2000-05-04 2002-04-16 Keith Chan, President Globoasia, Llc Synthesis of 1,8-dichloro-anthracene analogues and pharmaceutical compositions based thereon
US6384049B1 (en) * 2000-05-25 2002-05-07 The Procter & Gamble Company Cancer treatment
US6395771B1 (en) * 2000-05-31 2002-05-28 Dabur Research Foundation Paclitaxel derivatives for the treatment of cancer
US6391916B1 (en) * 2000-07-21 2002-05-21 The Hong Kong University Of Science And Technology Enediyne derivatives

Also Published As

Publication number Publication date
EA003326B1 (ru) 2003-04-24
JP2002531396A (ja) 2002-09-24
BR9915940A (pt) 2001-09-11
WO2000032175A3 (en) 2000-08-03
EA200100502A1 (ru) 2001-12-24
HUP0201215A2 (en) 2002-08-28
EE200100302A (et) 2002-08-15
TR200101549T2 (tr) 2001-11-21
US20020048271A1 (en) 2002-04-25
NO20012737L (no) 2001-07-09
WO2000032175A2 (en) 2000-06-08
JP2006166920A (ja) 2006-06-29
NO20012737D0 (no) 2001-06-01
YU35401A (sh) 2005-07-19
IL143094A0 (en) 2002-04-21
IS5943A (is) 2001-05-15
PL348310A1 (en) 2002-05-20
KR20010086073A (ko) 2001-09-07
EP1137418A2 (en) 2001-10-04
CA2350597A1 (en) 2000-06-08
CN1329493A (zh) 2002-01-02
ZA200104210B (en) 2003-02-24
HRP20010414A2 (en) 2002-06-30
AP2001002153A0 (en) 2001-06-30
OA11722A (en) 2005-01-25
HK1041644A1 (zh) 2002-07-19
AU1290700A (en) 2000-06-19
BG105599A (en) 2002-02-28

Similar Documents

Publication Publication Date Title
ID29061A (id) METODE DAN KOMPOSISI UNTUK MEMPERBAIKI STABILITAS KONFORMASI SUATU PROTEIN DARI KELUARGA p53
PT1066027E (pt) Composicao farmaceutica de topiramato
ATA69098A (de) Stoffgemisch zur topischen anwendung
DE69614690D1 (de) Herstellung von grossen hohlformigen verbundstrukturen
NO993068L (no) Ny forbindelsesform
CY2012029I2 (el) Nεα μορφη της 5-ομεπραζολης
ID27724A (id) Penstabil sediaan parmasi dari turunan-turunan asam gamma-aminobutira dan proses pembuatannya
PT1005328E (pt) Composicao compreendendo particulas de budesonido cristalinas finamente divididas
ATE319406T1 (de) Kompositmaterialien aus calciumverbindungen und proteinkomponenten
EE200200328A (et) Multši kompositsioon ja meetod
BR9509712A (pt) Composição de redeção de pregas
DK1308455T3 (da) Sammensætning omfattende anti-HER2-antistoffer
DE69915204D1 (de) Stabilisierte Proteinzusammensetzung
DE60019960D1 (de) Herstellung von isobutencopolymere
DE69937171D1 (de) Verfahren zur Herstellung von arylierten Poly-alpha-Olefinen
EE04717B1 (et) Indolüülpiperidiinühendid, nende valmistamismeetod, kompositsioon ja nende kasutamine
ID30135A (id) Komposisi-komposisi dan metode-metode untuk mengontrol serangga-serangga
EE04681B1 (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
ID26137A (id) Komposisi farmasi baru dari uridin trifosfat
DE59915061D1 (de) Herstellung von strukturierten elektroden
EE200100314A (et) Meetod farmatseutilise kompositsiooni valmistamiseks, farmatseutiline kompositsioon ja selle kasutamine
ATE212225T1 (de) Injizierbare arzneizubereitung bestehend aus paracetamol
ID21569A (id) Komposisi hormonal terdiri dari senyawa estrogen dan senyawa progrestasional
DE69913556D1 (de) Herstellung von aminen
DE69524976D1 (de) Herstellung von [11C] Methyljodid